Tax Services for
Pharmaceutical Companies
in UAE
The definitive 2026 tax guide for UAE pharmaceutical companies — VAT on medicines and medical devices, Corporate Tax optimisation, import duties on APIs, R&D deductions, transfer pricing, and full regulatory tax compliance.
Pharmaceutical companies operating in the UAE face one of the most technically complex tax environments of any industry sector — combining the UAE's relatively new but increasingly enforced VAT and Corporate Tax frameworks with sector-specific regulatory requirements from the Ministry of Health (MoHAP), Dubai Health Authority (DHA), Abu Dhabi Department of Health (DoH), and the UAE's customs and import duty regime on active pharmaceutical ingredients (APIs), finished drug products, and medical devices. While many pharmaceutical products benefit from the UAE VAT zero-rating on registered medicines, this exemption is narrow and frequently misapplied, creating costly FTA audit exposures. Meanwhile, Corporate Tax at 9% — with genuine QFZP optimisation opportunities for free zone pharma manufacturers and distributors — import duty management through Designated Zone bonded warehousing, R&D cost deductibility for clinical trial and drug development investments, and transfer pricing on API supply agreements and intercompany distribution arrangements all create a tax landscape that requires specialist, sector-specific professional support. This comprehensive 2026 guide covers every material tax obligation and planning opportunity for UAE pharmaceutical companies — VAT treatment of medicines, medical devices and pharma services, Corporate Tax and QFZP structure, customs and import duty optimisation, R&D deductions, transfer pricing for multinational pharma groups, regulatory compliance costs, and how OneDeskSolution provides specialist UAE pharma tax advisory services.
💊1. UAE Pharmaceutical Industry & Tax Context 2026
The UAE pharmaceutical market is one of the largest and fastest-growing in the Middle East — driven by a rapidly expanding healthcare system, a government commitment to reducing import dependency through domestic pharmaceutical manufacturing, a large and diverse expatriate population with sophisticated healthcare expectations, and the UAE's strategic position as a GCC regional hub for pharmaceutical distribution and healthcare services. The UAE's pharmaceutical market is valued at over USD 3.5 billion and growing at approximately 7–10% annually.
From a tax perspective, the pharmaceutical sector in the UAE is uniquely complex. Unlike most industries where VAT treatment is relatively straightforward — 5% standard rate on most supplies — pharmaceutical companies must navigate a matrix of zero-rated supplies (registered medicines), standard-rated supplies (non-medicine healthcare products, pharma services), import duty on APIs and finished products (with potential Designated Zone suspensions), and a Corporate Tax environment that offers genuine planning opportunities through QFZP free zone status for manufacturing and distribution operations.
The FTA has specifically identified pharmaceutical companies as a sector requiring enhanced compliance monitoring — partly because the VAT zero-rating for "qualifying medicines" is frequently misapplied, partly because import VAT recovery on pharmaceutical products is complex, and partly because multinational pharmaceutical companies operating through UAE entities have significant transfer pricing obligations that are not always properly documented. Understanding the full tax landscape specific to UAE pharma is essential for compliant, efficient operations.
Specialist Tax Advisory for UAE Pharmaceutical Companies
OneDeskSolution's tax team understands the unique VAT, customs, and Corporate Tax challenges of UAE pharmaceutical companies — from medicine zero-rating and API import duty management to QFZP optimisation, R&D deductions, and transfer pricing compliance. Contact us today.
🧪2. VAT on Medicines, APIs & Medical Devices
The VAT treatment of pharmaceutical products in the UAE is governed by the UAE VAT Executive Regulations, specifically the provisions on qualifying healthcare supplies. The key principle is that only medicines and medical equipment that meet specific MoHAP registration and listing criteria qualify for zero-rating — all other pharmaceutical and health-related products are standard-rated at 5%.
| Product Category | VAT Rate | Qualifying Condition | Documentation Required |
|---|---|---|---|
| Registered prescription medicines (human) | Zero-Rated (0%) | Registered on MoHAP UAE medicines list; intended for human use | MoHAP registration certificate; product listing confirmation; invoice showing MoHAP registration number |
| Registered OTC medicines (human) | Zero-Rated (0%) | Registered OTC product on MoHAP list; sold through licensed pharmacy | MoHAP OTC registration; sales channel confirmation (licensed pharmacy) |
| Active Pharmaceutical Ingredients (APIs) | Standard-Rated (5%) | APIs are raw materials — not finished registered medicines. Zero-rating does not extend to APIs | Standard 5% VAT invoice; input VAT recoverable by registered manufacturer |
| Medical devices (Class I, II, III — MDMA registered) | Zero-Rated (0%) | Registered medical devices listed in the UAE Medical Devices and Medicaments Agency (MDMA) database | MDMA registration certificate; device classification documentation |
| Veterinary medicines | Standard-Rated (5%) | Zero-rating applies to human medicines only; veterinary products are 5% VAT | Standard 5% VAT invoice; veterinary licence documentation |
| Nutritional supplements / vitamins | Standard-Rated (5%) | Supplements not registered as medicines attract standard 5% VAT even if sold in pharmacies | Standard 5% VAT invoice; product classification confirmation |
| Cosmetics / personal care sold in pharmacy | Standard-Rated (5%) | Cosmetics are not medicines — 5% VAT regardless of pharmacy sales channel | Standard 5% VAT invoice |
| Diagnostic test kits (MDMA registered) | Zero-Rated (0%) | Registered diagnostic devices on MDMA list qualify for zero-rating | MDMA registration; device listing reference on invoice |
| Hospital equipment / surgical instruments (MDMA) | Zero-Rated (0%) | MDMA-registered medical equipment for healthcare use — zero-rated | MDMA registration certificate; intended use confirmation |
| Unregistered / sample products | Standard-Rated (5%) | Products without MoHAP/MDMA registration cannot be zero-rated regardless of product type | Standard 5% VAT; apply for registration to achieve zero-rating |
The Single Most Common Pharma VAT Error: Applying zero-rating to products that are not on the MoHAP medicines register or MDMA device register — based on the assumption that "healthcare products" are generally zero-rated. They are not. Zero-rating is strictly limited to products with confirmed MoHAP or MDMA registration. Supplements, vitamins, cosmeceuticals, veterinary products, and unregistered products sold by pharmaceutical companies are all 5% standard-rated, even if the company's primary business is registered medicines. Blanket zero-rating of all pharmaceutical company output is a serious FTA audit finding with 50% penalty on the under-declared VAT amount.
🔬3. VAT on Pharmaceutical Services
| Service Type | VAT Treatment | Rate | Key Note |
|---|---|---|---|
| Contract manufacturing services (CMO) | Standard-Rated | 5% | Manufacturing services supplied to UAE pharma companies — 5% VAT; input recoverable by buyer |
| Pharmaceutical distribution services | Standard-Rated | 5% | Logistics, warehousing, distribution management services to UAE clients — 5% VAT |
| Clinical trial management services | Standard-Rated | 5% | CRO services provided within UAE — 5% VAT; complex where trials span multiple jurisdictions |
| Regulatory affairs / MoHAP registration consulting | Standard-Rated | 5% | Professional consulting services — 5% VAT to UAE clients |
| Pharma R&D services to overseas groups | Zero-Rated (export) | 0% | Where benefit received outside UAE — export of services conditions must be met with full documentation |
| Medical education / CME to healthcare providers | Standard-Rated | 5% | Educational services provided to healthcare professionals — 5% unless separate healthcare exemption applies |
| Pharmacovigilance services | Standard-Rated | 5% | Drug safety monitoring services to UAE clients — 5% VAT |
| Royalty / licence fees on drug patents (received) | Standard-Rated | 5% | If patent owner is UAE-registered and licences to UAE entity — VAT applies; overseas licensor: reverse charge |
🔄 Reverse Charge on Overseas Pharma Services Received
Overseas CRO Services
UAE pharma company paying an overseas Contract Research Organisation for clinical trial management — reverse charge 5% VAT on each invoice. Declare Box 3, recover Box 10.
Overseas Regulatory Consulting
Payments to overseas regulatory affairs consultants for non-UAE market registration support — reverse charge applies if service benefit received in UAE.
Patent / Licence Fees to Overseas Parent
UAE affiliate paying royalties to overseas IP holding entity for drug formulation patents — reverse charge applies to royalty payments received from overseas licensor.
Overseas Research Partners
Payments to overseas universities, research institutes, or specialist labs — reverse charge on all overseas research service invoices received by UAE entity.
🏛️4. Corporate Tax for UAE Pharmaceutical Companies
| CT Scenario | Rate | Conditions | Key Actions |
|---|---|---|---|
| Free Zone Manufacturer (QFZP) | 0% on qualifying income | Qualifying income >95%; UAE substance (factory, staff); arm's-length TP on API supply and intercompany distribution | Annual QFZP election; monthly qualifying income monitoring; substance documentation; annual TP review |
| Mainland Pharma Distributor | 9% above AED 375K profit | Standard CT rules; IFRS-based taxable income; UAE mainland activities | Quarterly CT provisioning; annual CT 201; non-deductibles add-back; statutory audit for financial statements |
| Small Business Relief (if eligible) | 0% (SBR election) | Revenue below AED 3M; most established pharma companies exceed this threshold | Actively elect SBR in CT return; cannot be QFZP simultaneously |
| Loss-making development phase | 0% (no taxable profit) | Pre-revenue or loss-making — clinical stage pharma companies | CT registration still mandatory; losses carried forward; annual CT 201 required |
💡 Key CT Deductible Expenses for Pharmaceutical Companies
- Manufacturing staff salaries and employment costs: All production staff, quality assurance, regulatory affairs, medical affairs, and sales team — fully deductible including housing allowance, health insurance, EOSB accrual, and visa costs
- API and raw material purchases: Cost of goods — APIs, excipients, packaging materials — fully deductible as cost of sales
- GMP facility costs: Clean room operation, equipment maintenance, calibration, utilities, facility rent — all deductible manufacturing overhead
- Clinical trial and R&D costs: See Section 7 for detailed treatment; generally deductible immediately when expensed, or via amortisation when capitalised
- MoHAP / DHA / MDMA registration fees: Regulatory registration costs — deductible as business expenses (may be capitalised as intangible assets under IAS 38 if they create separately identifiable future economic benefits)
- Client entertainment: Hospitality provided to healthcare professionals (HCPs) — 50% non-deductible under CT rules AND subject to UAE Code of Pharmaceutical Marketing Practices restrictions. Double compliance exposure
- Fines and regulatory penalties: MoHAP fines, DHA penalties, MOHRE fines — fully non-deductible; must be added back in CT return computation
🏭5. QFZP Optimisation for Free Zone Pharma Companies
UAE free zone pharmaceutical manufacturers, distributors, and biotech companies can access 0% Corporate Tax on qualifying income through QFZP status — a significant advantage for companies with primarily international or intra-group sales. The key free zones used by UAE pharmaceutical companies each offer different infrastructure and customs advantages.
| Free Zone | Pharma Advantage | DZ Status | Key Facilities |
|---|---|---|---|
| JAFZA (Jebel Ali) | GCC re-export hub; bonded warehousing for API and finished product; cold chain logistics | Designated Zone ✓ | Temperature-controlled warehouses; proximity to Jebel Ali Port; GDP-compliant logistics |
| Dubai Science Park | Dedicated life sciences ecosystem; MoHAP registration support; pharma-specific infrastructure | Standard | GMP labs, R&D facilities; biotech incubator; healthcare cluster |
| Dubai Industrial City | Pharmaceutical manufacturing cluster; GMP-compliant factory units; large-scale production | Standard | Industrial zoning; factory units 500–50,000 m²; proximity to logistics hubs |
| Abu Dhabi KIZAD | AD pharma market access; Khalifa Port connectivity; large manufacturing plots | Designated Zone ✓ | Industrial land for GMP manufacturing; direct port access; ADNOC supply chain links |
| RAK Pharma Hub (RAKIA) | Lower operating cost; established pharma manufacturing cluster; QFZP eligible | Standard | GMP-compliant factory units; established pharma community; cost-effective utilities |
QFZP for Pharma — The De Minimis Challenge: Many UAE pharmaceutical companies have both international/GCC customer revenue (qualifying) and UAE domestic hospital/pharmacy sales (non-qualifying UAE mainland revenue). For QFZP status, UAE mainland customer revenue must stay below the de minimis threshold — lesser of AED 5M or 5% of total revenue. A growing UAE domestic sales operation can inadvertently breach this threshold and lose 0% CT status for the entire year. Companies with significant UAE domestic pharma sales should assess whether a dual-entity structure (free zone entity for export/GCC business + mainland distributor for UAE domestic) is more appropriate than a single QFZP entity attempting to cover both markets.
📦6. Customs Duties & Import Management
| Import Category | Standard Duty Rate | GCC Common Tariff Code | Key Notes |
|---|---|---|---|
| Registered finished medicines (human) | 0% (exempt) | HS 30.01–30.06 | Most registered human pharmaceuticals — zero duty under UAE/GCC tariff. MoHAP registration required for duty-free entry |
| Active Pharmaceutical Ingredients (APIs) | 5% standard rate | Various HS 29.xx | Raw material APIs attract 5% CIF-basis duty; no general exemption for pharmaceutical use without specific approval |
| Pharmaceutical excipients | 5% (most categories) | Various HS codes | Packaging materials, binders, fillers — 5% duty; no medicine exemption for excipients alone |
| Medical devices (MDMA registered) | 0% or 5% | HS 90.18–90.22 | Many MDMA-registered devices are duty-free; some categories at 5% — verify specific HS code with customs broker |
| Lab equipment / analytical instruments | 5% | HS 90.27 | Quality control and QA lab equipment — 5% CIF basis; recoverable as business asset in CT |
| Cold chain / refrigerated products | 0% (if registered medicine) | Various | Biologics, vaccines — duty-free if MoHAP registered; special customs handling documentation required for cold chain |
🏭 Designated Zone Customs Strategy for Pharma Manufacturers
- DZ bonded warehousing: Import APIs and raw materials into JAFZA or KIZAD Designated Zone — customs duty and VAT on import are suspended until materials leave the DZ for the UAE mainland. For a pharmaceutical manufacturer processing APIs into finished products that are primarily exported to GCC/international markets, duty on APIs may never be payable at all
- Re-export advantage: APIs and packaging materials imported into DZ, processed into finished medicines, and re-exported to GCC or international markets may exit the DZ without ever paying UAE customs duty — eliminating the duty cost entirely for export-oriented manufacturers
- UAE domestic sales from DZ: When finished medicines leave the DZ for the UAE mainland (sale to UAE hospitals, pharmacies, or distributors), UAE customs duty on the API/raw material content becomes payable. Track the UAE/export split of production carefully
- GDP compliance: All pharmaceutical imports must comply with Good Distribution Practice (GDP) requirements — temperature-controlled logistics documentation, chain of custody records, and MoHAP import permit for each shipment. Non-compliant imports may be seized at customs regardless of duty status
- VAT on import recovery: Where UAE VAT at 5% is paid at customs on API or other imports by a VAT-registered pharmaceutical manufacturer, this import VAT is recoverable in the quarterly VAT return (Box 6 — Import VAT). Ensure your customs broker's import declarations are linked to your VAT records for recovery
Pharma Tax is Complex. We Know the Sector.
OneDeskSolution provides specialist pharmaceutical company tax services — from medicine VAT zero-rating reviews and API import duty management through QFZP optimisation, clinical trial R&D deductions, and transfer pricing compliance. Contact us for expert pharma tax advisory.
🔬7. R&D & Clinical Trial Cost Deductions
| R&D Cost Category | IFRS Treatment (IAS 38) | CT Deductibility | Timing |
|---|---|---|---|
| Basic scientific research | Always expensed — IAS 38 prohibits capitalising research phase costs | Immediately deductible in year incurred | Year of expense |
| Pre-clinical development costs | Expensed — IAS 38 feasibility criteria not yet met at pre-clinical stage | Immediately deductible | Year of expense |
| Phase I–III clinical trial costs | Generally expensed — outcome uncertain; technical feasibility not established until Phase III success | Immediately deductible (typically) | Year of expense |
| Phase III success → registration costs | May be capitalised as intangible — technical feasibility established; future economic benefits probable | Deductible via amortisation over registration life | Over useful life (5–20 years) |
| Drug patent acquisition | Capitalised as intangible asset at purchase cost | Amortised over patent remaining life | Over patent term |
| Contract Research Organisation (CRO) fees | Expensed or capitalised per phase per above | Deductible (expensed) or amortised (capitalised) | Per accounting treatment |
| Regulatory submission fees (MoHAP) | May be expensed or capitalised — company policy | Deductible as business expense | Year of expense (if expensed) |
| Pharma R&D staff costs | Expensed — employment costs not separable from research phase | Fully deductible as employment cost | Year of payment / accrual |
Clinical Trial Cost Deductibility — Practical Guidance: Most pharmaceutical companies in the UAE expense clinical trial costs as incurred — correctly reflecting the high failure rate of drug development and the ongoing uncertainty of outcome. This maximises immediate CT deductions. Where a drug successfully completes Phase III and regulatory approval is imminent, the accounting team should assess whether subsequent registration and commercialisation costs meet IAS 38 capitalisation criteria — because from that point, amortisation (rather than immediate deduction) may apply. Our advisory team can review your current R&D cost accounting policy for both IFRS compliance and CT optimisation.
🔗8. Transfer Pricing for Multinational Pharmaceutical Groups
Transfer pricing is one of the highest-risk tax areas for multinational pharmaceutical companies with UAE entities — because the typical pharma group structure (overseas IP holder, UAE manufacturing affiliate, UAE distribution affiliate, regional HQ) creates multiple intercompany transaction flows that must all be priced at arm's length and documented.
| Intercompany Transaction | TP Method | Risk Level | Documentation Required |
|---|---|---|---|
| API supply from parent to UAE manufacturer | Comparable Uncontrolled Price (CUP) or cost-plus | High | Benchmarking study; supply agreement; pricing methodology memo |
| Drug patent royalty paid to overseas IP holder | CUP or profit split; royalty rate benchmarking | High | IP valuation; royalty rate benchmark; licence agreement; BEPS alignment |
| Finished product supply from UAE manufacturer to group distributors | Resale Price Method (RPM) or TNMM | Medium | Transfer price formula; distribution agreement; margin benchmarking |
| Management fees / HQ charges to UAE affiliate | Cost-plus or TNMM | Medium | Services description; time allocation; benchmarked rate; annual reconciliation |
| Clinical trial cost sharing | Cost Contribution Arrangement (CCA) | High | CCA agreement; contribution formula; anticipated benefit allocation; annual true-up |
| Distribution services to GCC affiliates | TNMM; distribution entity return | Medium | Distribution agreement; benchmarked operating margin; arm's-length confirmation |
- UAE CT TP Local File threshold: If your UAE pharmaceutical entity has related-party transactions exceeding AED 3M per year, a TP Local File must be prepared contemporaneously and attached to the CT return. "Contemporaneously" means it must exist at the time of filing — not prepared retrospectively after an FTA audit inquiry
- Master File requirement: If your global pharmaceutical group has consolidated revenue above AED 3.15 billion (EUR 750M equivalent), Country-by-Country Reporting (CbCR) obligations may apply. UAE entities in such groups must file the UAE CbCR notification via EmaraTax
- Royalty rate scrutiny: The FTA is specifically focused on high-value intercompany royalty arrangements in the pharmaceutical sector, given the potential for artificial profit shifting via royalty payments to low-tax IP holding jurisdictions. Royalty rates must be benchmarked using recognised databases (BvD Royalty Range, ktMINE) with sector-specific comparable data
- API transfer price documentation: Where a UAE pharma manufacturer purchases APIs from an overseas affiliate, the transfer price must reflect the arm's-length price for the same API from independent suppliers — adjust for quality, volume, and credit terms. Generic API market data is typically available for CUP benchmarking
📋9. Regulatory Registration & Compliance Costs
| Regulatory Cost | Annual / Per Event | CT Deductibility | VAT Recovery |
|---|---|---|---|
| MoHAP product registration fees | AED 2,000–20,000+ per product | Deductible (or capitalised as intangible) | Input VAT recoverable |
| DHA / DoH licence fees (distribution) | AED 5,000–50,000+ annually | Fully deductible as operating cost | Input VAT recoverable (5% charged) |
| MDMA medical device registration | AED 3,000–15,000 per device | Deductible (or capitalised) | Input VAT recoverable |
| GMP inspection / WHO PIC/S fees | Varies by facility size | Fully deductible — operating cost | Input VAT recoverable |
| Pharmacovigilance system maintenance | Annual SaaS / service costs | Deductible — reverse charge if overseas SaaS | Reverse charge input VAT recoverable |
| Cold chain certification / GDP audit | Per audit cycle | Fully deductible | Input VAT recoverable |
| MOHRE fines / regulatory penalties | Variable | Non-deductible — add-back in CT | No VAT recovery on fines |
📅10. Annual Tax Compliance Calendar — Pharma Companies
Classify all revenue by VAT treatment (zero-rated medicines vs. standard-rated services/products). Calculate reverse charge on all overseas CRO, regulatory consultant, and SaaS invoices. Track QFZP income split (UAE domestic vs. GCC/international sales). Accrue EOSB for all staff. WPS payroll processing.
File VAT 201. Box 1: standard-rated UAE supplies (pharma services, APIs, non-qualifying products). Box 4: zero-rated qualifying medicines. Box 3: reverse charge on overseas CRO/consultant/SaaS invoices. Box 6: import VAT recovery. Box 10: input VAT on standard-rated purchases. Pay net VAT due.
Same as above for Q1. Mid-year review of QFZP income split and de minimis threshold status. Assess whether R&D costs should be expensed or capitalised for IFRS and CT purposes.
File and pay Q2 VAT. Review R&D expenditure coding. Check import duty management effectiveness — DZ utilisation review. CT mid-year provision update.
File and pay Q3 VAT. Full-year CT position estimate. Review TP documentation — confirm intercompany transactions are within agreed benchmarked ranges. Year-end tax planning: timing of deductible R&D expenditure.
IFRS financial statements audit — mandatory for all free zone pharmaceutical companies. Engage MoE-registered auditor. Review R&D capitalisation vs. expensing decisions. Confirm EOSB provision accuracy. See our audit services page for pharmaceutical company audit expertise.
File CT 201 via EmaraTax. Include: QFZP election, non-deductible add-backs (entertainment 50%, fines 100%), R&D cost treatment confirmation, TP Disclosure Form (if related-party transactions >AED 3M). Pay net CT liability.
🏆11. Our Pharmaceutical Tax Services
VAT Zero-Rating Review
Medicine and device portfolio classification; MoHAP/MDMA registration verification; zero-rating vs. standard-rated product mapping
Quarterly VAT Returns
Full VAT 201 — zero-rated medicines, reverse charge on overseas services, import VAT recovery (Box 6), multi-rate portfolio management
QFZP Monitoring
Monthly income split: UAE domestic vs. international sales; de minimis dashboard; dual-entity structure advisory
Corporate Tax Return
Annual CT 201, R&D cost treatment, non-deductibles review, TP Disclosure Form, QFZP election, statutory audit coordination
Transfer Pricing
TP Local File, royalty benchmarking, API supply pricing, CCA documentation, intercompany agreement review
Customs & Import Advisory
DZ bonded warehousing strategy, API duty management, import VAT recovery, customs classification review
❓12. Frequently Asked Questions
Expert Tax Advisory for UAE Pharmaceutical Companies
From medicine VAT zero-rating classification and API import duty management through QFZP Corporate Tax optimisation, clinical trial R&D deductions, transfer pricing Local Files, and annual statutory audit — OneDeskSolution provides the specialist pharmaceutical tax and accounting support your UAE operations need. Contact us for a free consultation.
